Publications by authors named "S Baklouti"
Introduction/objectives: Psoriatic arthritis (PsA) is a chronic inflammatory rheumatism belonging to the spondyloarthritis family. It is a multifactorial disease whose genetic determinism is still poorly understood. It is favored by environmental factors in genetically predisposed individuals.
View Article and Find Full Text PDFMavacamten, the first drug in the class of β-cardiac myosin modulator, is used for the treatment of patients with hypertrophic cardiomyopathy. This orally administered drug demonstrates wide interpatient variability in pharmacokinetics parameters, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 poor metabolizers have increased exposure and are at increased risk of reduced cardiac hypercontractility.
View Article and Find Full Text PDFArticle Synopsis
- * A case involving a 16-year-old showed elevated inflammatory markers and imaging revealed significant bone damage and infections in the pubic area.
- * The patient responded well to a 2-month antibiotic treatment, highlighting the importance of early diagnosis and intervention to improve recovery outcomes.
This study introduces a novel wearable Inertial Measurement Unit (IMU)-based system for an objective and comprehensive assessment of Work-Related Musculoskeletal Disorders (WMSDs), thus enhancing workplace safety. The system integrates wearable technology with a user-friendly interface, providing magnetometer-free orientation estimation, joint angle measurements, and WMSDs risk evaluation. Tested in a cable manufacturing facility, the system was evaluated with ten female employees.
View Article and Find Full Text PDFArticle Synopsis
- Aminoglycosides can cause nephrotoxicity and ototoxicity, which can be monitored, but genetic predispositions related to the MT-RNR1 gene can heighten the risk of ototoxicity from the first dose.* -
- The Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Francophone Pharmacogenetics Network (RNPGx) provide recommendations on genetic testing for variants of the MT-RNR1 gene that affect ototoxicity, emphasizing the need for thorough screening if aminoglycoside treatment can be delayed.* -
- RNPGx recommends testing for specific MT-RNR1 variants before administering aminoglycosides, but acknowledges the challenge of conducting these tests quickly in urgent situations, and